Pharmaceuticals

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

Pharmalot Ed Silverman

STAT Plus: Biden administration appeals jury finding in battle over patents for HIV prevention pills

Exclusive Nicholas Florko and J. Emory Parker

STAT Plus: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors

Politics Rachel Cohrs Zhang

STAT Plus: Judge rules against Boehringer Ingelheim in pharma’s latest legal loss on Medicare negotiation

Pharmalot Ed Silverman

STAT Plus: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes

Pharma Adam Feuerstein

STAT Plus: GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the third quarter: 19 stock-moving events to watch

Pharmalot Ed Silverman

STAT Plus: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents

Pharmalot Ed Silverman

STAT Plus: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

Health Lev Facher

STAT Plus: Upending Purdue Pharma’s settlement does little to help today’s opioid crisis, advocates say

The Readout LOUD Allison DeAngelis and Brittany Trang

Listen: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

Business Associated Press

Walgreens could shutter hundreds of underperforming stores

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed

The Readout Elaine Chen

STAT Plus: One firm, two conflicting takes on Alnylam’s HELIOS-B 

Pharmalot Ed Silverman

STAT Plus: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Biotech Adam Feuerstein

STAT Plus: What the Sarepta decision means for Duchenne patients, the company, and the FDA

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors? 

Biotech Elaine Chen

STAT Plus: Zealand’s amylin-targeting drug shows early potential in obesity

Exclusive Ed Silverman

STAT Plus: Doctors Without Borders is closing its widely regarded access-to-medicines campaign

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more

The Readout Elaine Chen

STAT Plus: Lilly takes more actions against unapproved versions of Mounjaro